Go Deep
Modalis Therapeutics Corporation
Modalis Therapeutics Corporation Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 21,280 | -1.1 | 1.14 | 0.11 | 16.34 |
Modalis Therapeutics Corporation Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -586,034,000.0 | -323,728,000.0 | -350,936,000.0 | -781,318,000.0 |
| EPS | — | -3.6 | — | — |
Modalis Therapeutics Corporation Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 40,500,000.0 | — |
| Net Profit | -2,152,710,000.0 | -1,317,894,000.0 | -2,391,821,000.0 | -2,702,709,000.0 | — |
| EPS | -27.9 | -28.6 | -77.2 | -92.8 | — |
Modalis Therapeutics Corporation Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 2,964,248,000.0 | 3,691,549,000.0 | 2,025,925,000.0 | 3,129,833,000.0 | — |
| Total Liabilities | 170,944,000.0 | 143,472,000.0 | 645,503,000.0 | 188,601,000.0 | — |
| Total Equity | 2,793,304,000.0 | 3,548,077,000.0 | 1,380,422,000.0 | 2,941,232,000.0 | — |
Owes vs Owns
Modalis Therapeutics Corporation owed ¥0.21 for every ¥1 it owned in Jun 2026, up from ¥0.06 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.21× | 0.06× | 0.04× | 0.32× | 0.06× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Modalis Therapeutics Corporation Assets & Liabilities Breakdown (JPY millions)
What it owns — Dec 2025
Cash & short-term investments 94.9%Other assets 5.1%
How it's funded — Dec 2025
Payables 3.2%Other liabilities 2.6%Shareholders' equity 94.2%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 2,812.4 | 3,575.3 | 1,883.4 | 2,933.2 |
| Receivables | 0.0 | 0.0 | 0.0 | 0.0 |
| Inventory | 0.0 | 0.1 | 6.4 | 40.3 |
| Fixed assets (tangible) | 0.0 | 0.0 | 0.0 | 0.0 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 151.9 | 116.1 | 136.1 | 156.4 |
| Liabilities & equity | ||||
| Short-term debt | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term debt | 0.0 | 0.0 | 412.5 | 0.0 |
| Payables | 94.4 | 79.3 | 99.1 | 110.1 |
| Other liabilities | 76.5 | 64.1 | 133.9 | 78.5 |
| Shareholders' equity | 2,793.3 | 3,548.1 | 1,380.4 | 2,941.2 |
| Net tangible assets | 2,793.3 | 3,548.1 | 1,380.4 | 2,941.2 |
Modalis Therapeutics Corporation Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -2,118,409,000.0 | -1,432,005,000.0 | -2,254,466,000.0 | -1,895,773,000.0 | — |
| Investing Activities | -2,571,000.0 | -188,000.0 | -39,699,000.0 | -185,719,000.0 | — |
| Financing Activities | 1,351,037,000.0 | 3,044,985,000.0 | 1,216,451,000.0 | 63,683,000.0 | — |